How to stay ahead with stronger biologics intellectual property searches

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

How to stay ahead with stronger biologics intellectual property searches

Sponsored by

Logo 22.07.22.png
artificial intelligence machine learning big data concept

Biologics intellectual property is complex and evolving rapidly, which makes effective searches vital. This CAS article presents expert strategies to address search challenges, protect innovations, and build stronger, litigation-ready patent programmes throughout the R&D life cycle

Effective searching is critical for protecting intellectual property (IP) and building stronger patent programmes in biologics R&D. However, the intricate nature of biologics innovation and IP – including sequence data, chemical modifications, and novel formulations – can make comprehensive searches challenging. This article presents several tips for securing biologics IP to safeguard your innovations, navigate regulatory frameworks, and mitigate potential litigation risks.

An opportunity and a challenge

Biologics IP has grown exponentially, creating opportunities for pharmaceutical companies to drive business value by developing stronger patent programmes at every stage of R&D.

Tips-for-stronger-graph.png

However, this growing volume of data adds another layer of complexity to an already challenging task. Though reliable sequence searches are crucial for pinpointing the business value of innovations during R&D and in building patent programmes to protect them, information on sequences is difficult to search and retrieve.

Pharmaceutical companies can encounter a number of obstacles that prevent efficient information access, including:

  • Sequence database records lacking essential information about chemical modifications;

  • Sequences claimed in different ways within patents;

  • Inconsistent descriptions of sequences in scientific and patent literature over time; and

  • Sequences as one component of complex inventions (such as antibody-drug conjugates with the antibody, drug payload, and linker).

These issues can lead to incomplete or inaccurate search results, which may hinder your ability to secure robust patent claims.

Foster collaboration across R&D, IP, and search

The complexity of biologics IP requires seamless collaboration between R&D, IP teams, outside counsel, and search professionals. Expectations, goals, and responsibilities should be aligned across all teams to reduce errors and ensure comprehensive search results. Searches should be treated as dynamic processes – results must be reviewed and refined as new data emerges during R&D, with each team member actively verifying scientific and patent data to minimise the risk of oversight.

Define your goals for strategic searching

When planning a search, focus not only on what you want to search for but also on the end goal. Approach the process with the question: “What would I be concerned about in a disclosed patent claim?” Sequence searches are inherently complex and demand more than traditional approaches:

  • Basic BLAST (basic local alignment search tool) or motif searches may not suffice, and queries often need to cover sequences, chemical modifications, keywords, and structures.

  • Skilled searchers leverage a variety of databases and platforms to create tailored strategies that efficiently handle large numbers of sequences.

  • The search process is iterative, evolving as results are reviewed. For instance, an initial request for a linker with five repeatable units may shift to evaluating linkers with fewer units to uncover nearby patent issues.

This flexible mindset ensures you capture a broader range of potential conflicts and comprehensive biologics IP insights that support informed decision making.

Leverage advanced analytical tools

Traditional methods of analysing search results can be highly manual, time consuming, and prone to human error, requiring searchers to spend days combing through citations and assembling reports. Data analytics platforms and analytical methods such as variation analysis can be used to interpret search results, significantly streamlining analysis and packaging data into reporting formats that can be easily filtered, reviewed, and understood.

Use freedom-to-operate searches throughout R&D

Think of your patent programme as an onion: a core composition of matter patent filing surrounded by protective patent filings for innovations that arise during R&D. Considering IP insights early and throughout R&D guides research, supports strong claims, and provides new layers of protection at every stage.

  • Lead development – Freedom-to-operate (FTO) searches can be performed with wide variability around the lead candidates to identify likely patent threats;

  • Proof of concept – FTO searches are used to clear core innovations and establish patentability, particularly when first-to-file status is critical for attracting investors; and

  • After phase two trials – additional FTO searches can be performed to clear novel uses, formulations, processes, and other innovations.

Continuously monitor the patent landscape

New patent applications are not published for 18 months, making continuous monitoring essential to staying ahead of potential threats. Your monitoring programme should alert you to:

  • Newly published patent applications that may affect ongoing R&D;

  • Scientific publications relevant to your work; and

  • Changes in the legal status or prosecution of patents.

This proactive approach ensures your team remains informed and prepared to adapt to emerging risks throughout the R&D process.

The complexities inherent in biologics require a sophisticated approach to IP searches. By adopting strategic search methodologies, leveraging specialised tools, and incorporating advanced analytics, organisations can build a stronger foundation for innovation protection. CAS IP Services works with leading biologics innovators to help to streamline their approach to patent monitoring and IP management. By collaborating with the CAS team, you can utilise its expertise in biologics IP to build a stronger patent programme and secure your future innovations.

more from across site and SHARED ros bottom lb

More from across our site

The firm is shaping its AI strategy around partnerships with Harvey and Legora alongside internally developed tools from its legal technology company, ELTEMATE
A dispute Down Under shows why trademark lawyers cannot afford to wait on the sidelines when a rival brand gathers momentum
The Third Circuit’s decision in Thomson Reuters v ROSS marks the first appellate-level decision addressing AI and fair use, prompting copyright counsel to consider arguments around potential licensing markets
Injunctions for HandsFree Labs and Align Technology come as the Court of Appeal warns that busy teams must have the staffing and resources to meet UPC deadlines
The chief technology officer remit, which has been created as the firm is building its litigation team, will include expanding the use of AI in patent and legal work and automating manual processes
Former Hoyng Rokh Moneiger partner Laura Alonso, who brought her team to ECIJA in March, discusses plans to expand further and why ECIJA’s ‘IP DNA’ is helping broaden her work
Amita Haylock discusses building an integrated Asia practice as clients increasingly demand that firms combine IP, technology and data expertise
François Pochart, Grégoire Desrousseaux and Lionel Martin, long-standing figures in the firm’s patent litigation team, are set to help launch a Paris-based litigation offering
The Unitary Patent has passed 100,000 registrations, but new data raises the question of whether 30% uptake is a ceiling or a staging post for further growth, say Michael Nielsen and Darren Smyth of EIP and Andrew Samm at Patently
The new generation of in-house IP leaders want commercial judgment, accessibility and flexibility, with AI raising expectations around both fees and delivery
Gift this article